Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

Thursday, July 12, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

References

_________________________________

i

AstraZeneca Canada Inc., Tagrisso® (osimertinib), Product Monograph. July 2018.

ii

Ibid.

iii

Soria J-C, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125

iv

Ibid.

v

Ibid.

vi

Ibid.

vii

Ibid.

viii

Soria J-C, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378:113-125

ix

Ibid.

x

Canadian Cancer Society. Lung Cancer Statistics. Accessed July 6, 2018. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=pe

xi

Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018. Available at:  http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf

xii

Ibid.

xiii

Molina JR, et al. Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc. 2008 May; 83(5): 584-594.

xiv

Lung Cancer Canada, The Faces of Lung Cancer Report 2017. Accessed January 26, 2018. Available at:  http://www.lungcancercanada.ca/LungCancerCanada/media/Documents/Faces-of-Lung-Cancer-Report-2017.pdf

xv

Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis. Oct 2013;5 Suppl 5:S579-592.

xvi

Dong, Lijun, Dan Lei, and Haijun Zhang. "Clinical Strategies for Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer Patients." Oncotarget 8.38 (2017): 64600–64606. PMC. Accessed on June 20, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610029/

xvii

Mazza, Valentina, and Federico Cappuzzo. "Treating EGFR Mutation Resistance in Non-Small Cell Lung Cancer – Role of Osimertinib." The Application of Clinical Genetics 10 (2017): 49–56. PMC. Accessed on June 20, 2018. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536882/



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store